Trial Profile
A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Dec 2012 Planned End Date changed from 1 Feb 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 12 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.